Zobrazeno 1 - 10
of 291
pro vyhledávání: '"H. Madariaga"'
Autor:
MV Gutierrez-Ardila, Jm Reyes, H Madariaga, W Otero, R Guzman, J Izquierdo, M Abello, P Velez, D Castillo, D Ponce de Leon, T Lukic, L Amador
Publikováno v:
Expert Review of Pharmacoeconomics & Outcomes Research. 22:787-794
To evaluate work productivity of adult Latin American patients with rheumatoid arthritis (RA) treated with tofacitinib and biological disease-modifying anti-rheumatic drugs (bDMARDs) measured by the Work Productivity and Activity Impairment (WPAI) in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::503fd2333fa81ed24415d372b29a6074
https://doi.org/10.1080/14737167.2022.2047935
https://doi.org/10.1080/14737167.2022.2047935
Publikováno v:
Medicentro, Vol 19, Iss 1, Pp 25-27 (2014)
Solanum melongena es una planta que se emplea principalmente con fines alimenticios. Diferentes estudios han informado su utilidad como hipolipemiante, antinflamatorio, antitumoral, entre otros. En estudios experimentales realizados en roedores, some
Externí odkaz:
https://doaj.org/article/c559e39428d049a3bbc394ba1e417dd1
Autor:
R. Guzman, J Izquierdo, J. Reyes, L. Amador, M Abello, W Otero, P Velez, Tatjana Lukic, D Castillo, MV Gutierrez, Dario Ponce de Leon, H. Madariaga
Objective: To describe the efficacy, safety and patient-reported outcomes (PROs) in patients with rheumatoid arthritis (RA) with an inadequate response to conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) treated with tofacitini
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3bf6fb31a58ba598062a9b9ae971a205
https://doi.org/10.21203/rs.3.rs-828468/v1
https://doi.org/10.21203/rs.3.rs-828468/v1
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Enrique R. Soriano, D. Ponce de Leon, Emilce Edith Schneeberger, Harry Shi, Gustavo Citera, Mario H. Cardiel, H. Madariaga, Daniela Graham, Thijs Hendrikx, Oswaldo Castañeda
Publikováno v:
FRIDAY, 15 JUNE 2018.
Background Non-alcoholic fatty liver disease, characterised by hepatic steatosis (HS), is a major cause of chronic liver disease in many countries. Limited data are available on liver enzyme elevation in patients (pts) with HS who are receiving medic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::45dbf6490e0e39ec40aa0b35252e4266
https://doi.org/10.1136/annrheumdis-2018-eular.2517
https://doi.org/10.1136/annrheumdis-2018-eular.2517
Autor:
D. Ponce de Leon, A. Ebrahim, Lori Stockert, F. Irazoque-Palazuelos, Lisy Wang, Ming-Ann Hsu, K. Santana, H. Madariaga, David Gruben, Gustavo Citera, R. Jain, R. Guzman
Publikováno v:
Annals of the Rheumatic Diseases. 79:318-319
Background:Depression/anxiety are common in RA pts. SF-36 MCS ≤38 can identify probable major depressive disorder and/or probable generalised anxiety disorder (pMDD/pGAD) in RA pts. Tofacitinib is an oral JAK inhibitor for the treatment of RA.Objec
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7c501aa9c36bcbb503204567ebfd9271
https://doi.org/10.1136/annrheumdis-2020-eular.417
https://doi.org/10.1136/annrheumdis-2020-eular.417
Publikováno v:
Value in Health. 24:S138
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fef1df058aa091cdda0d2ffd3d0fd1bd
https://doi.org/10.1016/j.jval.2021.04.679
https://doi.org/10.1016/j.jval.2021.04.679
Publikováno v:
Value in Health. 24:S143
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c9808e209e8e5d31c67e570f29f83fd0
https://doi.org/10.1016/j.jval.2021.04.704
https://doi.org/10.1016/j.jval.2021.04.704
Publikováno v:
Value in Health. 24:S142
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::dbbde42b7babf1fbf7b8d9159a61c740
https://doi.org/10.1016/j.jval.2021.04.699
https://doi.org/10.1016/j.jval.2021.04.699
Autor:
LJ Elizondo, Marcia Pinheiro, L Gόrriz, D. Ponce de Leon, LF Medina, Emilce Edith Schneeberger, Rdn Giorgi, JC Sarmiento-Monroy, A Salas, B Garro, RD Mantilla, H. Madariaga, JB Zacariaz
Publikováno v:
Abstracts Accepted for Publication.
Background Tofacitinib is an oral JAK inhibitor for the treatment of RA. Tofacitinib can be given as monotherapy or with csDMARDs. Published data on real world (RW) tofacitinib use in Latin America (LA) are limited. We characterise the patient (pt) p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::932e266cda497e3db8372b19af9368c1
https://doi.org/10.1136/annrheumdis-2017-eular.1607
https://doi.org/10.1136/annrheumdis-2017-eular.1607